Lipoprotein Testing denials: what the review data shows
Independent reviewers have decided 12 published cases where an insurer denied Lipoprotein Testing — and they overturned the insurer 0% of the time. A denial for Lipoprotein Testing is a starting position, not a final answer.
Conditions behind lipoprotein testing denials
| Category | Decisions | Overturned |
|---|---|---|
| Hyperlipidemia | 5 | 0% |
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for gene panel testing and/or the advanced lipoprotein testing. Lipoprotein(a) is a causal independent risk factor for atherosclerotic cardiovascular disease events. The risk of atherosclerotic cardiovascular disease events has been shown to increase linearly with lipoprotein(a) concentrations. The National Lipid Association (NLA) stated that lipoprotein(a) testing may be reasonable to refine atherosclerotic cardiovascular disease risk in adults with specific risk factors. Per the NLA, a personal history of premature atherosclerotic cardiovascular disease, primary severe hypercholesterolemia, or suspected familial hypercholesterolemia, or for patients with first-degree relatives with premature atherosclerotic cardiovascular disease.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested reimbursement for advanced lipoprotein testing, including lipoprotein (a). Advanced lipoprotein testing may provide additional risk stratification for atherosclerotic cardiovascular disease; however, current clinical guidelines do not recommend routine use in low risk individuals or in patients without established indications. Management decisions in most patients remain based on standard lipid panels and overall cardiovascular risk assessment, with treatment focused on established therapies such as statins.In this case, there is no documentation of high risk conditions such as established atherosclerotic cardiovascular disease, diabetes mellitus, or a strong family history that would support the need for advanced lipoprotein testing.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Lipoprotein Testingwhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY